OncoPharm
John Bossaer
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Episodes
Mentioned books
Jan 19, 2023 • 13min
Adjuvant Interferon In Melanoma
The Landmarks in OncoPharm series returns to discuss adjuvant interferon in melanoma.
ECOG 1684: https://pubmed.ncbi.nlm.nih.gov/?term=36649675
Commentary on E1684: https://ascopubs.org/doi/abs/10.1200/JCO.22.02354
Jan 12, 2023 • 20min
Breast Cancer In A Nutshell
Broad, big picture overview of breast cancer and its treatment.
Ambitious.
Do not recommend listening at 1.5x
Jan 5, 2023 • 21min
Mosunetuzumab And Same-day Pegfilgrastim w/ ddAC
New Year - New Drug, mosunetuzumab (a CD3-CD20 T-cell engager) is approved for r/r Follicular Lymphoma.
And an intriguing retrospective cohort study found a higher rate of neutropenia with same-day pegfilgrastim in patients receiving dose-dense AC. Link: https://doi.org/10.1177/10781552221148116
Dec 29, 2022 • 20min
2022 New Drug Review
This gift-giving season, we ask whether we want to Keep, Re-gift, or Return new oncology drugs approved this past year.
Dec 22, 2022 • 17min
Project Renewal: Capecitabine
The FDA's pilot program, project renewal, uses capecitabine for its first label makeover. What's new & what are the possible implications of the DPYD warning now in the prescribing information?
Dec 16, 2022 • 15min
ASH 2022 Highlights
Thought on:
Double Dauno, but they said it better --> (https://open.spotify.com/episode/0eHEl3bUdZdg3mynUiNMG6?si=88cdab4b882e4667)
Blinatumumab FTW
The end of "the" neutropenic diet?
Dec 8, 2022 • 18min
TILs, Olutasidenib, T-DXd
Tumor-Infiltrating Lymphocytes (TILs) getting closer to entering practice.
Updated survival results published from DESTINY-Breast03 (T-DXd vs. T-DM1).
A new IDH1 inhibitor, olutasidenib, is FDA-approved for relapsed or refractory AML.
Dec 1, 2022 • 14min
Bad News For Belantamab-Mafodotin And Atezolizumab's Bladder Cancer Indication
Recent voluntary withdrawals from the US market of belantamab-mafodotin and atezolizumab's indication for bladder cancer have us weighing (again) the pros & cons of the accelerated approval program.
Also, FDA approves the 1st fecal transplant product.
Nov 17, 2022 • 19min
Mirvetuximab Soravtansine
A new antibody-drug conjugate is approved for ovarian cancer.
Nov 10, 2022 • 14min
Metastatic NSCLC Updates: Role of CTLA-4 inhibitors?
We review the 5-year update of CheckMate 227 and the POSEIDON to generate the hypothesis that CLTA-4 inhibition has a role in PD-L1 negative metastatic NSCLC.
CM 227 update: https://pubmed.ncbi.nlm.nih.gov/?term=36223558
POSEIDON: https://pubmed.ncbi.nlm.nih.gov/?term=36327426
Editorial: https://pubmed.ncbi.nlm.nih.gov/?term=36331243
